Power priors and type I error control: constrained borrowing of external control data.

IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Se Yoon Lee
{"title":"Power priors and type I error control: constrained borrowing of external control data.","authors":"Se Yoon Lee","doi":"10.1080/10543406.2025.2575940","DOIUrl":null,"url":null,"abstract":"<p><p>Recently, hybrid designs have garnered significant attention in the healthcare industry due to their potential to improve statistical power and trial efficiency by augmenting randomized controlled trial data with external controls. The power prior methodology provides a versatile framework for constructing and analyzing data from hybrid designs. However, the use of external control data poses a risk of introducing bias, particularly in the presence of prior-data conflict, which can distort treatment effect estimates. Such biases may lead to erroneous conclusions, including the approval of ineffective treatments or the rejection of beneficial ones. To address these concerns, it is essential to borrow an appropriate amount of external data to maintain the type I error rate at an acceptable level, typically determined during trial planning in discussion with regulatory authorities. In this article, we present a novel power prior method to incorporate historical control data while safeguarding against inflation of the type I error rate beyond the maximally allowable nominal level. Through comprehensive simulation studies and an illustrative example, we demonstrate the practical advantages of our approach. The results illustrate that our method provides trial sponsors with a scientifically rigorous strategy for leveraging external control data in constructing efficient and reliable hybrid designs.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1161-1183"},"PeriodicalIF":1.3000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2575940","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/12 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Recently, hybrid designs have garnered significant attention in the healthcare industry due to their potential to improve statistical power and trial efficiency by augmenting randomized controlled trial data with external controls. The power prior methodology provides a versatile framework for constructing and analyzing data from hybrid designs. However, the use of external control data poses a risk of introducing bias, particularly in the presence of prior-data conflict, which can distort treatment effect estimates. Such biases may lead to erroneous conclusions, including the approval of ineffective treatments or the rejection of beneficial ones. To address these concerns, it is essential to borrow an appropriate amount of external data to maintain the type I error rate at an acceptable level, typically determined during trial planning in discussion with regulatory authorities. In this article, we present a novel power prior method to incorporate historical control data while safeguarding against inflation of the type I error rate beyond the maximally allowable nominal level. Through comprehensive simulation studies and an illustrative example, we demonstrate the practical advantages of our approach. The results illustrate that our method provides trial sponsors with a scientifically rigorous strategy for leveraging external control data in constructing efficient and reliable hybrid designs.

功率先验和I型误差控制:外部控制数据的约束借用。
最近,混合设计在医疗保健行业引起了极大的关注,因为它们有可能通过增加外部控制的随机对照试验数据来提高统计能力和试验效率。功率优先方法为构建和分析混合设计数据提供了一个通用的框架。然而,使用外部控制数据会带来引入偏差的风险,特别是在存在先验数据冲突的情况下,这可能会扭曲治疗效果的估计。这种偏见可能导致错误的结论,包括批准无效的治疗方法或拒绝有益的治疗方法。为了解决这些问题,有必要借用适当数量的外部数据,将第一类错误率维持在可接受的水平,这通常是在与监管当局讨论的试验计划期间确定的。在本文中,我们提出了一种新的功率先验方法来结合历史控制数据,同时防止第一类错误率超过最大允许的名义水平的膨胀。通过全面的仿真研究和实例说明,我们证明了该方法的实际优势。结果表明,我们的方法为试验发起人提供了一种科学严谨的策略,可以利用外部控制数据构建高效可靠的混合设计。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书